Gentian Diagnostics ASA announced that it has been granted a patent in the U.S. for its product candidate NT-proBNP. NT-proBNP is a non-invasive biomarker for the diagnosis of congestive heart failure (CHF). An aging population and lifestyle choices increase the cost burden in healthcare systems and thereby drive demand for NT-proBNP testing.

Gentian's assay, which is currently under development, aims to be the first turbidimetric IVD test for NT-proBNP supporting improved laboratory throughput and productivity. Additionally, Gentian aims to contribute to easier standardisation of test results. In its Third Quarter 2022 report, Gentian gave an update on the progress made on NT-proBNP currently in the optimisation phase.

A working prototype was established in the quarter and additional testing is ongoing. Further, the establishment of the reference method at the first trial site has been accomplished supporting the process of calibrating the immunoassay towards commercially available products. The patent for NT-proBNP is issued by the U.S. Patent and Trademark Office.